Targeting the Elongin BC – BC ‐Box Interface: Structural Insights, Peptidic Disruptors and Emerging Small‐Molecule Strategies
Chemical Biology & Drug Design · 2026-05 · 107 (5)
DOI: 10.1111/cbdd.70307 ↗At a glance
Übersichtsarbeit in Chemical Biology & Drug Design, published online on 2026-05-03. Written by Emadeldin M Kamel and 5 co-authors. Institution: Chemistry Department, Faculty of Science, Beni-Suef University, Beni-Suef, Egypt. Major MEDLINE topics: Elongin, Peptides, Small Molecule Libraries. 54 references. Funded by: Imam Mohammad Ibn Saud Islamic University (IMSIU), Imam Mohammed Ibn Saud Islamic University.
Abstract (original language)
Protein–protein interactions (PPIs) that orchestrate ubiquitin‐dependent signaling have long challenged drug discovery because their interfaces are typically large and hydrophobic. The heterodimeric adaptor Elongin BC (ELOB/ELOC) defies this stereotype: its BC‐box–binding groove is a deep, rigid pocket that anchors dozens of cellular and viral partners to cullin‐RING ligases and to transcriptional machinery. Recent structural and chemical‐biology breakthroughs have converted this once “undruggable” site into a tractable target. A sub‐nanomolar peptide derived from the chromatin factor EPOP has been shown to displace native BC‐box proteins, trigger apoptosis in multiple cancer lines, and unveil a transcriptomic signature that converges on MYC and cell‐cycle control. Parallel fragment screens and crystallography have mapped adjacent hot spots suitable for small‐molecule growth, while functional genomics highlights Elongin BC as a pan‐cancer dependency and an unexpected regulator of the SARS‐CoV‐2 co‐receptor TMPRSS2. This review synthesizes the structural principles of BC‐box recognition, the current state of peptide and fragment‐based inhibitors, and the biological consequences of disrupting the Elongin BC hub. We discuss therapeutic prospects in oncology and virology, outline key challenges—delivery, selectivity, and resistance—and propose future directions ranging from stapled‐peptide optimization to covalent fragment tethering and PROTAC strategies. Together, these advances position Elongin BC inhibition at the forefront of next‐generation PPI drug discovery, offering a unified approach to modulate ubiquitin signaling, epigenetic regulation, and viral entry through a single conserved pocket.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Chemistry Department, Faculty of Science, Beni-Suef University, Beni-Suef, Egypt.
- Department of Biology, College of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia.
- Physiology Division, Zoology Department, Faculty of Science, Beni-Suef University, Beni-Suef, Egypt.
- Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah, Saudi Arabia.
- Departamento de Química and Institute for Advanced Research in Chemical Science (IAdChem), Facultad de Ciencias, Módulo 13, Universidad Autónoma de Madrid, Madrid, Spain.
ORCID profiles: Emadeldin M Kamel, Noha A Ahmed, Al Mokhtar Lamsabhi
Funding
- Imam Mohammad Ibn Saud Islamic University (IMSIU)
- Imam Mohammed Ibn Saud Islamic University
Cite
APA
Kamel, E. M., Khadrawy, S. M., Allam, A. A., Ahmed, N. A., Aba Alkhayl, F. F., & Lamsabhi, A. M. (2026). Targeting the Elongin BC – BC ‐Box Interface: Structural Insights, Peptidic Disruptors and Emerging Small‐Molecule Strategies. Chemical Biology & Drug Design, 107(5). https://doi.org/10.1111/cbdd.70307
Vancouver
Kamel EM, Khadrawy SM, Allam AA, Ahmed NA, Aba Alkhayl FF, Lamsabhi AM. Targeting the Elongin BC – BC ‐Box Interface: Structural Insights, Peptidic Disruptors and Emerging Small‐Molecule Strategies. Chemical Biology & Drug Design. 2026;107(5). doi:10.1111/cbdd.70307
BibTeX
@article{Kamel2026,
author = {Kamel, Emadeldin M and Khadrawy, Sally Mostafa and Allam, Ahmed A and Ahmed, Noha A and Aba Alkhayl, Faris F and Lamsabhi, Al Mokhtar},
title = {Targeting the Elongin BC – BC ‐Box Interface: Structural Insights, Peptidic Disruptors and Emerging Small‐Molecule Strategies},
journal = {Chemical Biology & Drug Design},
year = {2026},
volume = {107},
number = {5},
doi = {10.1111/cbdd.70307}
}
EUVIMED